Abstract
RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Volume: 9 Issue: 3
Author(s): Gabriel Courties, Jessy Presumey, Isabelle Duroux-Richard, Christian Jorgensen and Florence Apparailly
Affiliation:
Keywords: RNA interference, gene therapy, inflammation, nanoparticles, immunotherapy
Abstract: RNA interference (RNAi) is an endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. Since its discovery RNAi has become the most widely used experimental tool providing powerful and sequence-specific knockdown of protein expression to elucidate the function of genes. The possibility of blocking the expression of any protein carries huge expectations for potential therapeutic applications in a wide range of diseases. For clinical development, however, the use of RNAi-based therapeutics has to overcome major drawbacks and disadvantages, mainly targeted delivery and safety issues. This review summarizes the current status of progress made in the development of efficient in vivo silencing; focusing on both viral and non viral delivery strategies, and provides an overview of specifications for anti-inflammatory RNAi-based gene therapy in preclinical models of immune- mediated inflammatory disorders such as rheumatoid arthritis, skin disorders and inflammatory bowel diseases.
Export Options
About this article
Cite this article as:
Courties Gabriel, Presumey Jessy, Duroux-Richard Isabelle, Jorgensen Christian and Apparailly Florence, Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (3) . https://dx.doi.org/10.2174/1871523011009030251
DOI https://dx.doi.org/10.2174/1871523011009030251 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial
Current Rheumatology Reviews Inflammation-Associated Changes in Bone Homeostasis
Inflammation & Allergy - Drug Targets (Discontinued) Is there a Potential Immune Dysfunction with Anabolic Androgenic Steroid Use?: A Review
Mini-Reviews in Medicinal Chemistry CD47 Functionalization of Nanoparticles as a Poly(ethylene glycol) Alternative: A Novel Approach to Improve Drug Delivery
Current Drug Targets Pharmacogenomics and Severe Infections: The Role of the Genomes of Both the Host and the Pathogen
Current Pharmacogenomics Studies on Growth Kinetics of Serratia marcescens VITSD2 and Optimization of Fermentation Conditions for Serratiopeptidase Production
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Phytochemical and Biological Activities of five Turanecio Hamzaoglu (Asteraceae) Species from Turkey
Current Enzyme Inhibition The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence
Reviews on Recent Clinical Trials OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Mechanism of Action of Strychni Semen for Treating Rheumatoid Arthritis and Methods for Attenuating the Toxicity
Combinatorial Chemistry & High Throughput Screening Inflammation: A Link Between Hypertension and Atherosclerosis
Current Hypertension Reviews Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease
Current Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Anti-Inflammatory Therapeutic Approaches to Reduce Acute Atherosclerotic Complications
Current Pharmaceutical Biotechnology Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) A Role for the Complement System in Rheumatoid Arthritis
Current Pharmaceutical Design Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Dehydroepiandrosterone in Therapy of Allergic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery IgG Dimers in Multidonor-Derived Immunoglobulins: Aspects of Generation and Function
Current Pharmaceutical Design